Cytokinetics' Aficamten Hits Dual Primary Endpoints in Pivotal Phase 3 Non-Obstructive HCM Trial
CYTK has more than doubled off its 52-week low of $29.31.
Summary
Cytokinetics announced highly positive topline results from its pivotal Phase 3 ACACIA-HCM clinical trial for aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The trial successfully met both dual primary endpoints, demonstrating statistically significant improvements in KCCQ-CSS and maximal exercise performance (pVO2) from baseline to Week 36 compared to placebo. Crucially, no new safety signals were identified, and positive findings were consistent across key secondary endpoints. This represents a significant de-risking event for aficamten, as there are currently no approved therapies for the underlying hypercontractility in nHCM, addressing a substantial unmet medical need. The strong data significantly enhances Cytokinetics' pipeline value and future revenue potential. Investors will now focus on the company's discussions with the FDA and other regulatory authorities regarding submission timelines and potential market approval.
At the time of this announcement, CYTK was trading at $81.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1B. The 52-week trading range was $29.31 to $70.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.